Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1991 Oct;59(10):3472–3477. doi: 10.1128/iai.59.10.3472-3477.1991

Contribution of individual toxin components to virulence of Bacillus anthracis.

C Pezard 1, P Berche 1, M Mock 1
PMCID: PMC258908  PMID: 1910002

Abstract

Three proteins, protective antigen (PA), lethal factor (LF), and edema factor (EF; a calmodulin-dependent adenylate cyclase), compose the lethal (PA + LF) and edema (PA + EF) toxins secreted by Bacillus anthracis. Mutant strains, each deficient in the production of one toxin component, were constructed, and their virulence was then studied. A kanamycin resistance cassette was inserted in each cya (encoding EF) and lef (encoding LF) gene, and the constructs were separately introduced into B. anthracis Sterne on a mobilizable shuttle plasmid. An EF- strain and an LF- strain were then isolated after homologous recombination with the resident toxin-encoding plasmid, pXO1. Spores from these mutants and from a previously constructed PA- mutant were used to inoculate mice, and the lethality and local edema formation were monitored. LF- or PA- mutants were not lethal even at high inocula, whereas the EF- mutant induced lethal infections. This indicates that LF in combination with PA is a key virulence factor required for lethality. Skin edema formation was observed with the LF- mutant, which produces only the combination of PA and EF. However, EF- and LF- mutants were significantly less efficient at inducing, respectively, lethality and edema than was the parental Sterne strain. These results suggest that the three toxin components might act synergistically in vivo to cause lethality and edema formation.

Full text

PDF
3472

Images in this article

3474Image
on p.3474

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Avakyan A. A., Katz L. N., Levina K. N., Pavlova I. B. Structure and composition of the Bacillus anthracis capsule. J Bacteriol. 1965 Oct;90(4):1082–1095. doi: 10.1128/jb.90.4.1082-1095.1965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. BEALL F. A., TAYLOR M. J., THORNE C. B. Rapid lethal effect in rats of a third component found upon fractionating the toxin of Bacillus anthracis. J Bacteriol. 1962 Jun;83:1274–1280. doi: 10.1128/jb.83.6.1274-1280.1962. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bragg T. S., Robertson D. L. Nucleotide sequence and analysis of the lethal factor gene (lef) from Bacillus anthracis. Gene. 1989 Sep 1;81(1):45–54. doi: 10.1016/0378-1119(89)90335-1. [DOI] [PubMed] [Google Scholar]
  4. Cataldi A., Labruyère E., Mock M. Construction and characterization of a protective antigen-deficient Bacillus anthracis strain. Mol Microbiol. 1990 Jul;4(7):1111–1117. doi: 10.1111/j.1365-2958.1990.tb00685.x. [DOI] [PubMed] [Google Scholar]
  5. Escuyer V., Duflot E., Sezer O., Danchin A., Mock M. Structural homology between virulence-associated bacterial adenylate cyclases. Gene. 1988 Nov 30;71(2):293–298. doi: 10.1016/0378-1119(88)90045-5. [DOI] [PubMed] [Google Scholar]
  6. Fish D. C., Klein F., Lincoln R. E., Walker J. S., Dobbs J. P. Pathophysiological changes in the rat associated with anthrax toxin. J Infect Dis. 1968 Feb;118(1):114–124. doi: 10.1093/infdis/118.1.114. [DOI] [PubMed] [Google Scholar]
  7. Fish D. C., Mahlandt B. G., Dobbs J. P., Lincoln R. E. Purification and properties of in vitro-produced anthrax toxin components. J Bacteriol. 1968 Mar;95(3):907–918. doi: 10.1128/jb.95.3.907-918.1968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Friedlander A. M. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J Biol Chem. 1986 Jun 5;261(16):7123–7126. [PubMed] [Google Scholar]
  9. Green B. D., Battisti L., Koehler T. M., Thorne C. B., Ivins B. E. Demonstration of a capsule plasmid in Bacillus anthracis. Infect Immun. 1985 Aug;49(2):291–297. doi: 10.1128/iai.49.2.291-297.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hambleton P., Carman J. A., Melling J. Anthrax: the disease in relation to vaccines. Vaccine. 1984 Jun;2(2):125–132. doi: 10.1016/0264-410x(84)90003-3. [DOI] [PubMed] [Google Scholar]
  11. Labruyère E., Mock M., Ladant D., Michelson S., Gilles A. M., Laoide B., Bârzu O. Characterization of ATP and calmodulin-binding properties of a truncated form of Bacillus anthracis adenylate cyclase. Biochemistry. 1990 May 22;29(20):4922–4928. doi: 10.1021/bi00472a024. [DOI] [PubMed] [Google Scholar]
  12. Ladant D. Interaction of Bordetella pertussis adenylate cyclase with calmodulin. Identification of two separated calmodulin-binding domains. J Biol Chem. 1988 Feb 25;263(6):2612–2618. [PubMed] [Google Scholar]
  13. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  14. Leppla S. H. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci U S A. 1982 May;79(10):3162–3166. doi: 10.1073/pnas.79.10.3162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Leppla S. H. Bacillus anthracis calmodulin-dependent adenylate cyclase: chemical and enzymatic properties and interactions with eucaryotic cells. Adv Cyclic Nucleotide Protein Phosphorylation Res. 1984;17:189–198. [PubMed] [Google Scholar]
  16. Leppla S. H. Production and purification of anthrax toxin. Methods Enzymol. 1988;165:103–116. doi: 10.1016/s0076-6879(88)65019-1. [DOI] [PubMed] [Google Scholar]
  17. Masure H. R., Shattuck R. L., Storm D. R. Mechanisms of bacterial pathogenicity that involve production of calmodulin-sensitive adenylate cyclases. Microbiol Rev. 1987 Mar;51(1):60–65. doi: 10.1128/mr.51.1.60-65.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Mikesell P., Ivins B. E., Ristroph J. D., Dreier T. M. Evidence for plasmid-mediated toxin production in Bacillus anthracis. Infect Immun. 1983 Jan;39(1):371–376. doi: 10.1128/iai.39.1.371-376.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Mock M., Labruyère E., Glaser P., Danchin A., Ullmann A. Cloning and expression of the calmodulin-sensitive Bacillus anthracis adenylate cyclase in Escherichia coli. Gene. 1988 Apr 29;64(2):277–284. doi: 10.1016/0378-1119(88)90342-3. [DOI] [PubMed] [Google Scholar]
  20. Ristroph J. D., Ivins B. E. Elaboration of Bacillus anthracis antigens in a new, defined culture medium. Infect Immun. 1983 Jan;39(1):483–486. doi: 10.1128/iai.39.1.483-486.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. STANLEY J. L., SMITH H. Purification of factor I and recognition of a third factor of the anthrax toxin. J Gen Microbiol. 1961 Sep;26:49–63. doi: 10.1099/00221287-26-1-49. [DOI] [PubMed] [Google Scholar]
  22. Smith H., Stoner H. B. Anthrax toxic complex. Fed Proc. 1967 Sep;26(5):1554–1557. [PubMed] [Google Scholar]
  23. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350–4354. doi: 10.1073/pnas.76.9.4350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Trieu-Cuot P., Carlier C., Poyart-Salmeron C., Courvalin P. Shuttle vectors containing a multiple cloning site and a lacZ alpha gene for conjugal transfer of DNA from Escherichia coli to gram-positive bacteria. Gene. 1991 Jun 15;102(1):99–104. doi: 10.1016/0378-1119(91)90546-n. [DOI] [PubMed] [Google Scholar]
  25. Trieu-Cuot P., Courvalin P. Nucleotide sequence of the Streptococcus faecalis plasmid gene encoding the 3'5"-aminoglycoside phosphotransferase type III. Gene. 1983 Sep;23(3):331–341. doi: 10.1016/0378-1119(83)90022-7. [DOI] [PubMed] [Google Scholar]
  26. Uchida I., Sekizaki T., Hashimoto K., Terakado N. Association of the encapsulation of Bacillus anthracis with a 60 megadalton plasmid. J Gen Microbiol. 1985 Feb;131(2):363–367. doi: 10.1099/00221287-131-2-363. [DOI] [PubMed] [Google Scholar]
  27. Welkos S. L., Friedlander A. M. Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice. Microb Pathog. 1988 Aug;5(2):127–139. doi: 10.1016/0882-4010(88)90015-0. [DOI] [PubMed] [Google Scholar]
  28. Welkos S. L., Friedlander A. M. Pathogenesis and genetic control of resistance to the Sterne strain of Bacillus anthracis. Microb Pathog. 1988 Jan;4(1):53–69. doi: 10.1016/0882-4010(88)90048-4. [DOI] [PubMed] [Google Scholar]
  29. Welkos S. L., Keener T. J., Gibbs P. H. Differences in susceptibility of inbred mice to Bacillus anthracis. Infect Immun. 1986 Mar;51(3):795–800. doi: 10.1128/iai.51.3.795-800.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Welkos S. L., Lowe J. R., Eden-McCutchan F., Vodkin M., Leppla S. H., Schmidt J. J. Sequence and analysis of the DNA encoding protective antigen of Bacillus anthracis. Gene. 1988 Sep 30;69(2):287–300. doi: 10.1016/0378-1119(88)90439-8. [DOI] [PubMed] [Google Scholar]
  31. Yanisch-Perron C., Vieira J., Messing J. Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. Gene. 1985;33(1):103–119. doi: 10.1016/0378-1119(85)90120-9. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES